Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Biogen Halts Mid-Stage IPF Drug Trial

Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.

Read More »

New Gene-Editing Tool, SATI, Focuses on Non-Coding Regions of the Genome

Researchers with the Salk Institute developed a new type of gene editing called SATI that may provide the option of editing numerous gene mutation diseases such as Huntington’s disease and the rare premature aging syndrome, progeria.

Read More »

Arizona State University Researchers Try Novel Approach to Alzheimer’s Prevention

Researchers at Arizona State University are experimenting with a compound that might prevent Alzheimer’s and other neurodegenerative diseases, such as Parkinson’s disease, and potentially Down syndrome.

Read More »

Rutgers’ Nanotechnology Research Might Help with Alzheimer’s, Parkinson’s and Other Diseases

Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.

Read More »

RegenxBio and Pfizer Partner on Gene Therapy

Rockville, Maryland-based RegenxBio entered a license deal with Pfizer for a gene therapy for Friedreich’s ataxia, the most common hereditary ataxia.

Read More »

InvaGen Receives FDA Approval for Generic of Pfizer’s Lyrica

The U.S. FDA approved InvaGen Pharmaceuticals’ generic version of Pfizer’s Lyrica (pregabalin) for eight different dosages.

Read More »

Genentech Strikes Three Drug Discovery Deals

In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.

Read More »

Two Genes Appear to Act as On/Off Switches for Neuroinflammation and Alzheimer’s Disease

Researchers with Massachusetts General Hospital have identified some crosstalk communication between TREM2 and CD33, two genes that play a role in inflammation and Alzheimer’s disease.

Read More »

Novartis, Amgen and Banner End Alzheimer’s Program

Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.

Read More »

Research Roundup: A New Protein Linked to Alzheimer’s and Other Highlights

Researchers at the RIKEN Center for Brain Science identified a new protein that might make the connection between amyloid plaques and tau in Alzheimer’s patients.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom